Sanara MedTech
SMTI
15 hedge funds and large institutions have $5.2M invested in Sanara MedTech in 2020 Q4 according to their latest regulatory filings, with 15 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
1.66% more ownership
Funds ownership: 0% → 1.66% (+1.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.33M |
| 2 |
Millennium Management
New York
|
+$415K |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
+$407K |
| 4 |
DC
Diametric Capital
Boston,
Massachusetts
|
+$225K |
| 5 |
AWA
Arete Wealth Advisors
Chicago,
Illinois
|
+$213K |
Top Sellers
SMTI Hedge Fund Activity: Q4 2020 in Review
15 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Sanara MedTech (SMTI) for Q4 2020, worth a combined $5.2M.
Buyers outnumbered sellers: 15 funds opened new SMTI positions and 0 closed out — a net gain of 15 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $2.33M.
- 15 institutional investors held Sanara MedTech (SMTI) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $5.2M of Sanara MedTech stock for Q4 2020.
- 15 funds opened new Sanara MedTech positions in Q4 2020 and 0 closed out, a net change of +15 holders.
- The largest Sanara MedTech buyer in Q4 2020 was Vanguard Group, an estimated $2.33M added.
Based on aggregated 13F filings for Q4 2020.